GlassScriptPhysician profile
Christopher Lee Chappell
NPI 1649651910
$721.49
in general payments reported to CMS, 2019-2025
19 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.84 · 2022: $27.14 · 2023: $17.14 · 2024: $424 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $79.01 | 2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $62.85 | 2024-2025 | Zenpep |
| Abbvie INC. | $61.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $60.32 | 2024-2025 | |
| Amgen INC. | $53.94 | 2024 | Prolia, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $48.13 | 2024-2025 | Breztri |
| Edwards Lifesciences Corporation | $43.21 | 2019-2022 | |
| Pfizer INC. | $37.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.79 | 2024-2025 | Ofev, Jardiance |
| Novo Nordisk INC | $36.74 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $35.39 | 2024-2025 | Zepbound, Mounjaro |
| Verity Pharmaceuticals INC. | $32.87 | 2025 | Tlando |
| Boston Scientific Corporation | $24.15 | 2024 | |
| Lundbeck LLC | $21.90 | 2024 | Rexulti |
| Medtronic, INC. | $21.56 | 2025 | Inceptiv |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $17.44 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $17.14 | 2023 | Austedo Xr |
| Dynavax Technologies Corporation | $15.89 | 2025 | Heplisav-B |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.